Zuo et al. (2019) demonstrated that hsa-miR-454 inhibited glioblastoma through down-regulating NFATc2 expression. Song identified that miR-454-3p accelerated the growth of cervical cancer via manipulating TRIM3 (Song et al., 2019). About the function of hsa-mir-454 in BRCA, one study found that MiR-454-3p may be used as diagnosis and treatment biomarker for BRCA metastasis patients (Ren et al., 2019). Here, NFATC2 is linked to glioblastoma.